Nonalcoholic fatty liver disease (NAFLD): Survey with the members of the Brazilian Hepatology Society;Doença hepática gordurosa não-alcoólica (DHGNA): Inquérito com membros da Sociedade Brasileira de Hepatologia

GED - Gastrenterologia Endoscopia Digestiva

Volumn 23, Issue 3, 2004, Pages 107-112

  Cotrim, Helma Pinchemel ^a   Pereira, Maria Leila ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; BRAZIL; CLINICAL FEATURE; CONTROLLED STUDY; DIET; E-MAIL; ECHOGRAPHY; EXERCISE; FEMALE; HEPATOLOGIST; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEDICAL SPECIALIST; NONALCOHOLIC FATTY LIVER; OBESITY; QUESTIONNAIRE; REVIEW; RISK FACTOR;

EID: 8744313979     PISSN: 01017772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic Proc 1980; 55: 434-8.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD. Hepatology 2003; 37: 1202-19.
3. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999; 34: 85-91.
4. Angulo P, Lindor KD. Nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17 (Suppl): S186-90.
5. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-7.
6. Sathya P, Martin S, Alvarez F. Nonalcoholic fatty liver disease (NAFLD) in children. Curr Opin Pediatr 2002; 14: 593-600.
7. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
8. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
9. Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999; 19: 299-304.
10. Cotrim HP, Freitas LA, Freitas C, Braga B, Sousa R, Carvalho F, et al. Clinical and histopathological features of NASH in workers exposed to chemicals with or without associated metabolic conditions. Liver International 2004; (24): 131-5.
11. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
12. Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an evolving diagnosis. Can J Gastroenterol 2000; 14: 321-6.
13. Shalhub S, Parsee A, Gallagher SF, Haines KL, Willkomm C, Brantley SG, et al. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obes Surg 2004; 14: 54-9.
14. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.
15. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
16. Brunt EM, Janney CJ, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999; 94: 2467-74.
17. Cotrim HP, Parana R, Braga E, Lyra L. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 2000; 95: 3018-9.
18. Angulo P. Current best treatment for nonalcoholic fatty liver disease. Expert Opin Pharmacother 2003; 4: 611-23.
19. Mendez-Sanchez N, Gonzalez V, Pichardo-Bahena R, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. Hepatology 2002; 36: 412A.
20. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 2003; 63: 2379-94.
21. Liangpunsakul S, Chalasani N. Treatment of nonalcoholic fatty liver disease. Curr Treat Options Gastroenterol 2003; 6: 455-63.